Pharma Focus Asia

Novo Nordisk Invests US$4.1 billion to Expand Production Capacity in USA

Introduction:

Novo Nordisk plans to invest U$4.1 billion towards constructing a second fill and finish manufacturing facility in the USA.

Features: 

The expansion project will increase production capacity significantly, adding 1.4 million square feet dedicated to aseptic manufacturing and finished production processes. This will effectively double the combined square footage of the current facilities located in North Carolina.

The new second fill and finishing manufacturing facility will enhance capabilities in producing both existing and future injectable treatments for conditions such as obesity and other serious chronic diseases.

Incorporating cutting-edge technology, including roof-top solar panels and advanced water management systems, the facility is designed to operate efficiently while prioritising environmental sustainability. Its primary goal is to ensure the delivery of high-quality products to patients worldwide.

The expansion is expected to create 1,000 new jobs in addition to the approximately 2,500 employees already contributing to the region, reinforcing its role as a prominent centre for innovation and biotechnology in the United States.

Construction is scheduled to proceed gradually, with completion anticipated between 2027 and 2029.

Specifications:

Name        Novo Nordisk
Type          Expansion
Budget    US$4.1 million 
Year          2029

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference